Senmed Medical Ventures

Investment decisions are led by Managing Partner Franklin M. Berger. Berger brings over two decades of sell-side biotech research experience to the role, having held senior analyst positions at J.P. Morgan, Goldman Sachs, and Salomon Smith Barney before founding the firm in 2016. The firm operates without a publicly named investment committee beyond Berger.

The firm typically targets early-stage to growth-equity healthcare companies that have reached clinical or regulatory inflection points. Berger's background in covering publicly traded biotech informs a preference for companies with near-term catalysts. The firm has engaged with pre-revenue and commercial-stage companies alike, often entering through advisory relationships that later convert to equity.

Available evidence points to direct investments and advisory engagements rather than fund-of-fund commitments. The firm has not publicly disclosed any limited partner positions in third-party venture funds. Its model appears built around concentrated, relationship-driven principal investments.

The firm does not publish a formal exclusion list. However, its historical positioning in digital health, medical devices, and services — rather than pure-play drug discovery — suggests a deliberate focus on capital-light healthcare business models. There is no public record of investments in provider networks or hospital systems.

The firm operates as an integrated advisory-and-investment platform. Berger provides strategic consulting to portfolio companies — often taking formal advisory or board roles — and deploys capital through the same entity. This structure differs from the typical venture capital firm, where advisory and investment functions are more clearly separated.